Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
CA 2499622 C · Owner: Novartis Ag · Inventors: Foster, Carolyn Ann; Hiestand, Peter C.; Glue, Paul William
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases e.g. , multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1P receptor agonist and b) at , least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 23, 2003 and granted January 3, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 23, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 23, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.